Oncology Institute Projects First Full Year of Adjusted EBITDA Profitability in 2026, Reaffirms 2025 Guidance
TOI has more than doubled off its 52-week low of $0.252.
Summary
The Oncology Institute, Inc. reaffirmed its 2025 financial guidance and provided a preliminary 2026 outlook, projecting its first full year of Adjusted EBITDA profitability and substantial revenue growth.
Key Events · Earnings and Guidance · TOI
-
Reaffirmed 2025 Guidance
The company reaffirmed its previously issued financial guidance for the full year 2025.
-
Preliminary 2026 Financial Outlook
For 2026, the company anticipates total revenue in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 guidance.
-
Projected Adjusted EBITDA Profitability
The Oncology Institute expects Adjusted EBITDA for 2026 to be in the range of $0 million to $9 million, with the midpoint representing its first full year of Adjusted EBITDA profitability as a public company.
-
Longer-Term Growth Projections
Beyond 2026, the company aims for approximately 20% annual revenue growth through 2028, with potential for mid-single-digit margin expansion as a percentage of revenue.
Analysis · TOI · Industrial Applications And Services
The Oncology Institute, Inc. has provided a strong financial outlook, projecting its first full year of Adjusted EBITDA profitability as a public company in 2026. This milestone, coupled with significant revenue growth expectations, indicates a positive shift in the company's financial trajectory and could significantly de-risk the investment thesis. The longer-term outlook further reinforces a path of continued expansion and margin improvement.
At the time of this filing, TOI was trading at $4.18 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $424M. The 52-week trading range was $0.25 to $4.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.